Asset Details
Do you wish to reserve the book?
Muscle-specific gene editing therapy via mammalian fusogen-directed virus-like particles
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Muscle-specific gene editing therapy via mammalian fusogen-directed virus-like particles
Do you wish to request the book?
Muscle-specific gene editing therapy via mammalian fusogen-directed virus-like particles
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Muscle-specific gene editing therapy via mammalian fusogen-directed virus-like particles
2025
Overview
Muscle genetic defects can lead to impaired movement, respiratory failure, and other severe symptoms. The development of curative therapies is challenging due to the need for the delivery of gene-editing tools into skeletal muscle cells throughout the body. Here, we use muscular fusogens (Myomaker and Myomerger) to engineer muscle-specific virus-like particles (MuVLPs) for the systemic delivery of gene-editing tools. We demonstrate that MuVLPs can be loaded with diverse payloads, including EGFP, Cre and Cas9/sgRNA ribonucleoproteins (Cas9 RNPs), and can be delivered into skeletal muscle cells via targeted membrane fusion. Systemic administration of MuVLPs carrying Cas9 RNPs enables skeletal muscle-specific gene editing, which excised the exon containing a premature terminator codon mutation in a mouse model for Duchenne muscular dystrophy (DMD). This treatment restores dystrophin expression in various skeletal muscle tissues, including the diaphragm, quadriceps, tibialis anterior, gastrocnemius, and triceps. As a result, the treated mice exhibit a significantly increased capacity for exercise and endurance. This study established a platform for precise gene editing in skeletal muscle tissues.
Genetic muscle diseases are difficult to treat due to challenges in delivering gene editors to muscles throughout the body. Here, authors engineer muscle-specific virus-like particles that fuse with skeletal muscle cells to deliver CRISPR tools and restore dystrophin in a DMD model.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ 42/44
/ Animals
/ CRISPR
/ CRISPR-Associated Protein 9 - genetics
/ CRISPR-Associated Protein 9 - metabolism
/ Duchenne's muscular dystrophy
/ Editing
/ Exons
/ HIV
/ Human immunodeficiency virus
/ Humanities and Social Sciences
/ Humans
/ Male
/ Mice
/ Muscle, Skeletal - metabolism
/ Muscles
/ Muscular Dystrophy, Duchenne - genetics
/ Muscular Dystrophy, Duchenne - therapy
/ Payloads
/ Plasmids
/ Proteins
/ Ribonucleoproteins - genetics
/ Ribonucleoproteins - metabolism
/ Science
/ Viruses
